162 related articles for article (PubMed ID: 25355412)
1. The B-box 1 dimer of human promyelocytic leukemia protein.
Huang SY; Naik MT; Chang CF; Fang PJ; Wang YH; Shih HM; Huang TH
J Biomol NMR; 2014 Dec; 60(4):275-81. PubMed ID: 25355412
[No Abstract] [Full Text] [Related]
2. Medicine. Poisonous contacts.
Kogan SC
Science; 2010 Apr; 328(5975):184-5. PubMed ID: 20378808
[No Abstract] [Full Text] [Related]
3. The RING domain of human promyelocytic leukemia protein (PML).
Huang SY; Chang CF; Fang PJ; Naik MT; Güntert P; Shih HM; Huang TH
J Biomol NMR; 2015 Feb; 61(2):173-80. PubMed ID: 25627356
[No Abstract] [Full Text] [Related]
4. Biophysical and functional analyses suggest that adenovirus E4-ORF3 protein requires higher-order multimerization to function against promyelocytic leukemia protein nuclear bodies.
Patsalo V; Yondola MA; Luan B; Shoshani I; Kisker C; Green DF; Raleigh DP; Hearing P
J Biol Chem; 2012 Jun; 287(27):22573-83. PubMed ID: 22573317
[TBL] [Abstract][Full Text] [Related]
5. ImageStream promyelocytic leukemia protein immunolocalization: in search of promyelocytic leukemia cells.
Mirabelli P; Scalia G; Pascariello C; D'Alessio F; Mariotti E; Di Noto R; George TC; Kong R; Venkatachalam V; Basiji D; Del Vecchio L
Cytometry A; 2012 Mar; 81(3):232-7. PubMed ID: 22266986
[TBL] [Abstract][Full Text] [Related]
6. Role of SUMO in RNF4-mediated promyelocytic leukemia protein (PML) degradation: sumoylation of PML and phospho-switch control of its SUMO binding domain dissected in living cells.
Percherancier Y; Germain-Desprez D; Galisson F; Mascle XH; Dianoux L; Estephan P; Chelbi-Alix MK; Aubry M
J Biol Chem; 2009 Jun; 284(24):16595-16608. PubMed ID: 19380586
[TBL] [Abstract][Full Text] [Related]
7. The PML gene of the PML-RARα V-form fusion transcript breaks within exon 6.
Qi X; Tan Y; Chen X; Bian S; Zhang L; Xu A; Xu Z; Wang H
Acta Haematol; 2011; 126(4):216-9. PubMed ID: 21934296
[No Abstract] [Full Text] [Related]
8. Solubility shift and SUMOylaltion of promyelocytic leukemia (PML) protein in response to arsenic(III) and fate of the SUMOylated PML.
Hirano S; Tadano M; Kobayashi Y; Udagawa O; Kato A
Toxicol Appl Pharmacol; 2015 Sep; 287(3):191-201. PubMed ID: 26049103
[TBL] [Abstract][Full Text] [Related]
9. Induction of promyelocytic leukemia (PML) oncogenic domains (PODs) by papillomavirus.
Nakahara T; Lambert PF
Virology; 2007 Sep; 366(2):316-29. PubMed ID: 17543368
[TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.
Zhang XW; Yan XJ; Zhou ZR; Yang FF; Wu ZY; Sun HB; Liang WX; Song AX; Lallemand-Breitenbach V; Jeanne M; Zhang QY; Yang HY; Huang QH; Zhou GB; Tong JH; Zhang Y; Wu JH; Hu HY; de Thé H; Chen SJ; Chen Z
Science; 2010 Apr; 328(5975):240-3. PubMed ID: 20378816
[TBL] [Abstract][Full Text] [Related]
11. The SUMO protease SENP6 is a direct regulator of PML nuclear bodies.
Hattersley N; Shen L; Jaffray EG; Hay RT
Mol Biol Cell; 2011 Jan; 22(1):78-90. PubMed ID: 21148299
[TBL] [Abstract][Full Text] [Related]
12. AXIN is an essential co-activator for the promyelocytic leukemia protein in p53 activation.
Li Q; He Y; Wei L; Wu X; Wu D; Lin S; Wang Z; Ye Z; Lin SC
Oncogene; 2011 Mar; 30(10):1194-204. PubMed ID: 21057547
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic targeting of nuclear receptor corepressor misfolding in acute promyelocytic leukemia cells with genistein.
Ng AP; Nin DS; Fong JH; Venkataraman D; Chen CS; Khan M
Mol Cancer Ther; 2007 Aug; 6(8):2240-8. PubMed ID: 17699721
[TBL] [Abstract][Full Text] [Related]
14. A CK2-dependent mechanism for degradation of the PML tumor suppressor.
Scaglioni PP; Yung TM; Cai LF; Erdjument-Bromage H; Kaufman AJ; Singh B; Teruya-Feldstein J; Tempst P; Pandolfi PP
Cell; 2006 Jul; 126(2):269-83. PubMed ID: 16873060
[TBL] [Abstract][Full Text] [Related]
15. Nuclear phospholipase C gamma: punctate distribution and association with the promyelocytic leukemia protein.
Ferguson BJ; Dovey CL; Lilley K; Wyllie AH; Rich T
J Proteome Res; 2007 May; 6(5):2027-32. PubMed ID: 17419608
[TBL] [Abstract][Full Text] [Related]
16. CK2 and PML: regulating the regulator.
Lallemand-Breitenbach V; de Thé H
Cell; 2006 Jul; 126(2):244-5. PubMed ID: 16873055
[TBL] [Abstract][Full Text] [Related]
17. Acute promyelocytic leukemia: from genetics to treatment.
Grignani F; Fagioli M; Alcalay M; Longo L; Pandolfi PP; Donti E; Biondi A; Lo Coco F; Grignani F; Pelicci PG
Blood; 1994 Jan; 83(1):10-25. PubMed ID: 8274729
[No Abstract] [Full Text] [Related]
18. Pondering the puzzle of PML (promyelocytic leukemia) nuclear bodies: can we fit the pieces together using an RNA regulon?
Borden KL
Biochim Biophys Acta; 2008 Nov; 1783(11):2145-54. PubMed ID: 18616965
[TBL] [Abstract][Full Text] [Related]
19. Geometric and potential driving formation and evolution of biomolecular surfaces.
Bates PW; Chen Z; Sun Y; Wei GW; Zhao S
J Math Biol; 2009 Aug; 59(2):193-231. PubMed ID: 18941751
[TBL] [Abstract][Full Text] [Related]
20. Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3.
Fu C; Ahmed K; Ding H; Ding X; Lan J; Yang Z; Miao Y; Zhu Y; Shi Y; Zhu J; Huang H; Yao X
Oncogene; 2005 Aug; 24(35):5401-13. PubMed ID: 15940266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
